Clinical trials: Clarithromycin, open to volunteers
Chemotherapy Effect
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
This study focuses on patients with H. pylori-positive resectable locally advanced adenocarcinoma of the gastric and oesophagogastric junction. It evaluates the perioperative oxaliplatin with S-1 (SOX) combined H.
- Trial name
- NCT06510010
- Testing
- Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate), Oxaliplatin With S-1 （SOX）
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Preterm Premature Rupture of Membranes (PPROM)
TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden
The goal of this clinical trial is to learn whether tailoring antibiotic and steroid treatment based on a lab result (interleukin-6, or IL-6) from amniotic fluid can help safely prolong pregnancy in people with preterm premature…
- Trial name
- TAILORED-PROM (NCT07107477)
- Testing
- Tailored antibiotic and steroid therapy based on the IL-6 value in amniotic fluid obtained by amniocentesis in patients with premature rupture of membranes, Antenatal steroids administration, Neuroprotection
- Where
- 3 sites in Czechia
- Volunteers
- 138 people
- Sponsor
- The Central and Eastern European Gynecologic Oncology Group
Sepsis
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with…
- Trial name
- CLASSIFY (NCT07834346)
- Testing
- clarithromycin
- Where
- 19 sites in Greece
- Volunteers
- 252 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Pulmonary Disease Due to Mycobacteria (Diagnosis)
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Mycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug resistant non-tuberculous mycobacteria (NTM) causing infections in humans.
- Trial name
- FORMaT (NCT04310930)
- Testing
- Amikacin, Tigecycline, Imipenem
- Where
- 50 sites in Australia, Denmark and 5 more
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
HELICOBACTER PYLORI INFECTIONS
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple…
- Trial name
- NCT07606833
- Testing
- Anaprazole Sodium enteric-coated tablet, Esomeprazole magnesium enteric-coated tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Helicobacter Infections
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
With the resistance of Helicobacter pylori increasing, low and unsatisfactory eradication rate (64%) have been observed with standard triple therapy in European children.
- Trial name
- NCT03365609
- Testing
- triple therapy, sequential therapy, bismuth quadruple therapy
- Where
- China
- Volunteers
- 1,440 people
- Sponsor
- Ying HUANG
Community-acquired Pneumonia
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early…
- Trial name
- REACT (NCT06294600)
- Testing
- Clarithromycin 500mg, Tablets
- Where
- 24 sites in Greece
- Volunteers
- 330 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Mycobacterium Abscessus Lung Disease
The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance
Background: Mycobacterium abscessus, one of the most common species of nontuberculous mycobacterium (NTM), poses a significant clinical challenge due to its natural resistance to antibiotics and high treatment failure rates…
- Trial name
- NCT07514364
- Testing
- Rifabutin, No Rifabutin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
This is an open-label, randomized controlled study. The study plans to enroll 414 subjects with Helicobacter pylori infection, who will be randomly assigned to the experimental group (Keverprazan dual therapy for 10 days or…
- Trial name
- NCT07122024
- Testing
- Keverprazan 10 days, Keverprazan 14 days, Rabeprazole
- Where
- China
- Volunteers
- 414 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Helicobacter Pylori Infection
Fecal Molecular Susceptibility-guided Hp Rescue Therapy
The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the rescue…
- Trial name
- NCT07405697
- Testing
- 7-day fecal molecular susceptibility-guided therapy, 14-day fecal molecular susceptibility-guided therapy
- Where
- 4 sites in China
- Volunteers
- 290 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric Cancer, H Pylori Infection
H. Pylori Screen-and-treat Study in a Population of Young Adults
Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe.
- Conditions
- Gastric Cancer, H Pylori Infection, H Pylori Eradication, H-pylori
- Trial name
- NCT06275204
- Testing
- Bismuth-based quadruple therapy, Levofloxacin-based quadruple therapy, Standard triple therapy
- Where
- 7 sites in Croatia, Ireland and 4 more
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Helicobacter Pylori Infection
Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children
Study of Nitazoxanide (NTZ) based therapeutic regimens for Helicobacter pylori in children
- Trial name
- NCT04415983
- Testing
- Nitazoxanide, Clarithromycin, Metronidazole
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Healthy Adult Volunteers
Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin
Drug-Drug Interaction between DW4421 and Amoxicillin/Clarithromycin
- Trial name
- NCT07382661
- Testing
- DW4421, DW4421-1, DW4421-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Helicobacter Pylori Infection
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without…
- Trial name
- NCT07439445
- Testing
- Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
HELICOBACTER PYLORI INFECTIONS
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
this Study Evaluating Safety and Effectiveness of (Proton Pump Inhibitor versus Vonoprazan) Based Triple Therapy with or without Zinc to Eradicate H. pylori Infection
- Trial name
- NCT07275827
- Testing
- zinc sulfate, Vonoprazan + amoxicillin + clarithromycin, proton pump inhibitor + amoxicillin
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Tanta University
Helicobacter Pylori Eradication
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2.
- Trial name
- NCT06349486
- Testing
- vonoprazan, amoxicillin, tripotassium dicitrate bismuthate, vonoprazan, amoxicillin, rabeprazole, amoxicillin, clarithromycin
- Where
- Taiwan
- Volunteers
- 390 people
- Sponsor
- Kaohsiung Medical University
HELICOBACTER PYLORI INFECTIONS
Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori
This prospective observational study aims to evaluate the feasibility and performance of real-time PCR (qPCR) performed on formalin-fixed, paraffin-embedded (FFPE) gastric biopsies to detect Helicobacter pylori infection and…
- Trial name
- HED-2T (NCT07821294)
- Testing
- q-PCR on FFPE gastric biopsies
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Clinique Bizet
Dyspepsia
Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection
The Goal of this this clinical trial is to assess and compare the eradication rate of triple and quadruple therapy during treating helicobacter pylori infection among patients presented with dyspepsia.
- Trial name
- NCT07010744
- Testing
- Triple drug regimen, Quadruple therapy
- Where
- Bangladesh
- Volunteers
- 66 people
- Sponsor
- Akil Al Islam
Helicobacter Pylori Infection
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
The prevalence of H. pylori antibiotic resistance has reached an alarming level worldwide. Antibiotic stewardship programs should be urgently developed and implemented. However, H.
- Trial name
- NCT05332444
- Testing
- susceptibility-guided tailored therapy (Group A), guidelines-recommended empiric therapy (Group B)
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Lung Infection, MAC Lung Disease
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
MAC lung infections are a growing public health problem. The ATS / IDSA 2007 guidelines for the treatment of these non-tuberculous mycobacterial infections recommend the use of a macrolide or azalide (clarithromycin or…
- Trial name
- CLAZI (NCT03236987)
- Testing
- Clarithromycin 1000 MG, Azithromycin 250 mg, Rifampicin
- Where
- 3 sites in France
- Volunteers
- 424 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens